Transcatheter aortic valve replacement in patients with severe comorbidities: A retrospective cohort study.
aortic stenosis
medical futility
outcome
transcatheter aortic valve replacement
Journal
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
ISSN: 1522-726X
Titre abrégé: Catheter Cardiovasc Interv
Pays: United States
ID NLM: 100884139
Informations de publication
Date de publication:
01 02 2021
01 02 2021
Historique:
received:
01
04
2020
accepted:
24
05
2020
pubmed:
9
6
2020
medline:
25
9
2021
entrez:
9
6
2020
Statut:
ppublish
Résumé
To investigate the long-term outcomes of patients with severe comorbidities (sCM) undergoing transcatheter aortic valve replacement (TAVR). The benefit of TAVR may be limited among patients with sCM due to a lack of mortality- or quality-of-life-benefit. All TAVR patients in the Allina Health System between January 1, 2011 and August 7, 2018 were included (n = 890, 82 ± 8 years, 55% men). sCM included: severe lung disease, severe liver disease, end-stage renal disease, severe, severe dementia, severe dilated cardiomyopathy, and frailty. Outcomes between patients with (n = 215, 24%) and without (n = 675, 76%) sCM were compared. At baseline, patients with sCM had worse symptoms, higher STS-PROM and a lower Kansas City Cardiomyopathy Questionnaire (KCCQ) score compared to those without. During a median follow-up of 15 months (IQR, 7-29 months), there were 208 (23%) deaths. Patients with sCM had a lower 3-year survival free from all-cause mortality (40% vs. 79%, p < .001), and lower 3-year survival free from the composite endpoint of all-cause mortality, re-hospitalization for heart failure, myocardial infarction or stroke (31% vs. 64%, p < .001) compared to those without sCM. The estimated monthly increase in KCCQ scores following TAVR was 1.5, 95%CI (1.3, 1.7), p < .001 irrespective of sCM grouping. From Cox regression analysis, severe comorbidities, with the exception of liver disease, were associated with an increased risk of all-cause mortality and any additional comorbidity was associated with a multiplicative increase in risk of mortality of 2.8 (95%CI 2.3, 3.6), p < .001. TAVR patients with sCM have poor 3-year outcomes but may experience improvements in their quality of life.
Sections du résumé
OBJECTIVE
To investigate the long-term outcomes of patients with severe comorbidities (sCM) undergoing transcatheter aortic valve replacement (TAVR).
BACKGROUND
The benefit of TAVR may be limited among patients with sCM due to a lack of mortality- or quality-of-life-benefit.
METHODS
All TAVR patients in the Allina Health System between January 1, 2011 and August 7, 2018 were included (n = 890, 82 ± 8 years, 55% men). sCM included: severe lung disease, severe liver disease, end-stage renal disease, severe, severe dementia, severe dilated cardiomyopathy, and frailty. Outcomes between patients with (n = 215, 24%) and without (n = 675, 76%) sCM were compared.
RESULTS
At baseline, patients with sCM had worse symptoms, higher STS-PROM and a lower Kansas City Cardiomyopathy Questionnaire (KCCQ) score compared to those without. During a median follow-up of 15 months (IQR, 7-29 months), there were 208 (23%) deaths. Patients with sCM had a lower 3-year survival free from all-cause mortality (40% vs. 79%, p < .001), and lower 3-year survival free from the composite endpoint of all-cause mortality, re-hospitalization for heart failure, myocardial infarction or stroke (31% vs. 64%, p < .001) compared to those without sCM. The estimated monthly increase in KCCQ scores following TAVR was 1.5, 95%CI (1.3, 1.7), p < .001 irrespective of sCM grouping. From Cox regression analysis, severe comorbidities, with the exception of liver disease, were associated with an increased risk of all-cause mortality and any additional comorbidity was associated with a multiplicative increase in risk of mortality of 2.8 (95%CI 2.3, 3.6), p < .001.
CONCLUSIONS
TAVR patients with sCM have poor 3-year outcomes but may experience improvements in their quality of life.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
E253-E262Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2017;38:2739-2791.
Mack MJ, Leon MB, Smith CR, et al. 5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomized controlled trial. Lancet. 2015;385:2477-2484.
Gleason TG, Reardon MJ, Popma JJ, et al. 5-year outcomes of self-expanding transcatheter versus surgical aortic valve replacement in high-risk patients. J Am Coll Cardiol. 2018;72:2687-2696.
Sorajja P, Kodali S, Reardon MJ, et al. Outcomes for the commercial use of self-expanding prostheses in transcatheter aortic valve replacement: a report from the STS/ACC TVT Registry. JACC Cardiovasc Interv. 2017;10:2090-2098.
Leon MB, Smith CR, Mack MJ, et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2016;374:1609-1620.
Thourani VH, Kodali S, Makkar RR, et al. Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis. Lancet. 2016;387:2218-2225.
Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med. 2019;380:1706-1715.
Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380:1695-1705.
Holmes DR Jr, Brennan JM, Rumsfeld JS, et al. Clinical outcomes at 1 year following transcatheter aortic valve replacement. JAMA. 2015;313:1019-1028.
Arnold SV, Reynolds MR, Lei Y, et al. Predictors of poor outcomes after transcatheter aortic valve replacement: results from the PARTNER (Placement of Aortic Transcatheter Valve) trial. Circulation. 2014;129:2682-2690.
Arnold SV, Spertus JA, Vemulapalli S, et al. Quality-of-life outcomes after transcatheter aortic valve replacement in an unselected population: a report from the STS/ACC transcatheter valve therapy registry. JAMA Cardiol. 2017;2:409-416.
Arnold SV, Cohen DJ, Dai D, et al. Predicting quality of life at 1 year after transcatheter aortic valve replacement in a real-world population. Circ Cardiovasc Qual Outcomes. 2018;11:e004693.
Puri R, Iung B, Cohen DJ, Rodes-Cabau J. TAVI or no TAVI: identifying patients unlikely to benefit from transcatheter aortic valve implantation. Eur Heart J. 2016;37:2217-2225.
Lindman BR, Alexander KP, O'Gara PT, Afilalo J. Futility, benefit, and transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2014;7:707-716.
Baumgartner HC, Hung JC-C, Bermejo J, et al. Recommendations on the echocardiographic assessment of aortic valve stenosis: a focused update from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. Eur Heart J Cardiovasc Imaging. 2017;18:254-275.
Saybolt MD, Fiorilli PN, Gertz ZM, Herrmann HC. Low-flow severe aortic stenosis: evolving role of transcatheter aortic valve replacement. Circ Cardiovasc Interv. 2017;10:e004838.
Stortecky S, Buellesfeld L, Wenaweser P, Windecker S. Transcatheter aortic valve implantation: the procedure. Heart. 2012;98(Suppl. 4):iv44-iv51.
Achenbach S, Delgado V, Hausleiter J, Schoenhagen P, Min JK, Leipsic JA. SCCT expert consensus document on computed tomography imaging before transcatheter aortic valve implantation (TAVI)/transcatheter aortic valve replacement (TAVR). J Cardiovasc Comput Tomogr. 2012;6:366-380.
Tang L, Lesser JR, Schneider LM, et al. Prospective evaluation for hypoattenuated leaflet thickening following transcatheter aortic valve implantation. Am J Cardiol. 2019;123:658-666.
Tang L, Gossl M, Ahmed A, et al. Contemporary reasons and clinical outcomes for patients with severe, symptomatic aortic stenosis not undergoing aortic valve replacement. Circ Cardiovasc Interv. 2018;11:e007220.
Dvir D, Waksman R, Barbash IM, et al. Outcomes of patients with chronic lung disease and severe aortic stenosis treated with transcatheter versus surgical aortic valve replacement or standard therapy: insights from the PARTNER trial (placement of AoRTic TraNscathetER Valve). J Am Coll Cardiol. 2014;63:269-279.
Allende R, Webb JG, Munoz-Garcia AJ, et al. Advanced chronic kidney disease in patients undergoing transcatheter aortic valve implantation: insights on clinical outcomes and prognostic markers from a large cohort of patients. Eur Heart J. 2014;35:2685-2696.
Tirado-Conte G, Rodes-Cabau J, Rodriguez-Olivares R, et al. Clinical outcomes and prognosis markers of patients with liver disease undergoing transcatheter aortic valve replacement: a propensity score-matched analysis. Circ Cardiovasc Interv. 2018;11:e005727.
Zusman O, Kornowski R, Witberg G, et al. Transcatheter aortic valve implantation futility risk model development and validation among treated patients with aortic stenosis. Am J Cardiol. 2017;120:2241-2246.
Rogers T, Alraies MC, Moussa Pacha H, et al. Clinical frailty as an outcome predictor after transcatheter aortic valve implantation. Am J Cardiol. 2018;121:850-855.
Arnold SV, Spertus JA, Lei Y, et al. How to define a poor outcome after transcatheter aortic valve replacement: conceptual framework and empirical observations from the placement of aortic transcatheter valve (PARTNER) trial. Circ Cardiovasc Qual Outcomes. 2013;6:591-597.
Kappetein AP, Head SJ, Généreux P, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the valve academic research Consortium-2 consensus document. Eur Heart J. 2012;33:2403-2418.
Bhatia N, Agrawal S, Yang S, et al. In-hospital outcomes of transcatheter aortic valve implantation in patients with end-stage renal disease on dialysis from a large national database. Am J Cardiol. 2017;120:1355-1358.
Gupta T, Goel K, Kolte D, et al. Association of chronic kidney disease with in-hospital outcomes of transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2017;10:2050-2060.
Oguri A, Yamamoto M, Mouillet G, et al. Impact of chronic kidney disease on the outcomes of transcatheter aortic valve implantation: results from the FRANCE 2 registry. EuroIntervention. 2015;10:e1-e9.
Suri RM, Gulack BC, Brennan JM, et al. Outcomes of patients with severe chronic lung disease who are undergoing transcatheter aortic valve replacement. Ann Thorac Surg. 2015;100:2136-2145.
Chopard R, Meneveau N, Chocron S, et al. Impact of chronic obstructive pulmonary disease on valve academic research consortium-defined outcomes after transcatheter aortic valve implantation (from the FRANCE 2 Registry). Am J Cardiol. 2014;113:1543-1549.
Mok M, Nombela-Franco L, Dumont E, et al. Chronic obstructive pulmonary disease in patients undergoing transcatheter aortic valve implantation: insights on clinical outcomes, prognostic markers, and functional status changes. JACC Cardiovasc Interv. 2013;6:1072-1084.
Crestanello JA, Popma JJ, Adams DH, et al. Long-term health benefit of transcatheter aortic valve replacement in patients with chronic lung disease. JACC Cardiovasc Interv. 2017;10:2283-2293.
Balanescu SM, Balanescu DV, Donisan T, et al. The onco-cardiologist dilemma: to implant, to defer, or to avoid transcatheter aortic valve replacement in cancer patients with aortic stenosis? Curr Cardiol Rep. 2019;21:83.
Watanabe Y, Kozuma K, Hioki H, et al. Comparison of results of transcatheter aortic valve implantation in patients with versus without active cancer. Am J Cardiol. 2016;118:572-577.
Mangner N, Woitek FJ, Haussig S, et al. Impact of active cancer disease on the outcome of patients undergoing transcatheter aortic valve replacement. J Interv Cardiol. 2018;31:188-196.
Landes U, Iakobishvili Z, Vronsky D, et al. Transcatheter aortic valve replacement in oncology patients with severe aortic stenosis. JACC Cardiovasc Interv. 2019;12:78-86.
Arnold SV, Afilalo J, Spertus JA, et al. Prediction of poor outcome after transcatheter aortic valve replacement. J Am Coll Cardiol. 2016;68:1868-1877.
Shimura T, Yamamoto M, Kano S, et al. Impact of the clinical frailty scale on outcomes after transcatheter aortic valve replacement. Circulation. 2017;135:2013-2024.
Okoh AK, Chauhan D, Kang N, et al. The impact of frailty status on clinical and functional outcomes after transcatheter aortic valve replacement in nonagenarians with severe aortic stenosis. Catheter Cardiovasc Interv. 2017;90:1000-1006.
Iung B, Laouénan C, Himbert D, et al. Predictive factors of early mortality after transcatheter aortic valve implantation: individual risk assessment using a simple score. Heart. 2014;100:1016-1023.
Martin GP, Sperrin M, Ludman PF, et al. Novel United Kingdom prognostic model for 30-day mortality following transcatheter aortic valve implantation. Heart. 2018;104:1109-1116.